0001193125-20-037802.txt : 20200214 0001193125-20-037802.hdr.sgml : 20200214 20200214143639 ACCESSION NUMBER: 0001193125-20-037802 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200214 DATE AS OF CHANGE: 20200214 GROUP MEMBERS: BIOTECH TARGET N.V. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Esperion Therapeutics, Inc. CENTRAL INDEX KEY: 0001434868 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-87536 FILM NUMBER: 20618159 BUSINESS ADDRESS: STREET 1: 3891 RANCHERO DRIVE, SUITE 150 CITY: ANN ARBOR STATE: MI ZIP: 48108 BUSINESS PHONE: 734-887-3903 MAIL ADDRESS: STREET 1: 3891 RANCHERO DRIVE, SUITE 150 CITY: ANN ARBOR STATE: MI ZIP: 48108 FORMER COMPANY: FORMER CONFORMED NAME: HDL THERAPEUTICS INC DATE OF NAME CHANGE: 20080513 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] IRS NUMBER: 000000000 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: SCHWERTSTRASSE 6 CITY: SCHAFFHAUSEN STATE: V8 ZIP: 8200 BUSINESS PHONE: 411724 59 59 MAIL ADDRESS: STREET 1: SCHWERTSTRASSE 6 CITY: SCHAFFHAUSEN STATE: V8 ZIP: 8200 SC 13G/A 1 d835892dsc13ga.htm SC 13G/A SC 13G/A

 

 

United States

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 5)*

 

 

ESPERION THERAPEUTICS, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

29664W105

(CUSIP Number)

December 31, 2019

(Date of Event Which Requires Filing This Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 29664W105  

 

  1.   

Names of Reporting Persons

 

BB Biotech AG

  2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)  ☒        (b)  ☐

 

  3.  

SEC Use Only

 

    

  4.  

Citizenship or Place of Organization

 

Switzerland

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

with:

    5.    

Sole Voting Power

 

0

   6.   

Shared Voting Power

 

3,727,964

   7.   

Sole Dispositive Power

 

0

   8.   

Shared Dispositive Power

 

3,727,964

  9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

3,727,964

10.  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares  ☐

 

    

11.  

Percent of Class Represented by amount in Row (9)

 

13.6%

12.  

Type of Reporting Person (See Instructions)

 

HC,CO

 

 

2 of 6

CUSIP No. 29664W105  

 

  1.   

Names of Reporting Persons

 

Biotech Target N.V.

 

I.R.S. Identification Nos. of above persons (entities only):

 

N/A

  2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)  ☒        (b)  ☐

 

  3.  

SEC Use Only

 

    

  4.  

Citizenship or Place of Organization

 

Curacao

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

with:

    5.    

Sole Voting Power

 

0

   6.   

Shared Voting Power

 

3,727,964

   7.   

Sole Dispositive Power

 

0

   8.   

Shared Dispositive Power

 

3,727,964

  9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

3,727,964

10.  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares  ☐

 

    

11.  

Percent of Class Represented by amount in Row (9)

 

13.6%

12.  

Type of Reporting Person (See Instructions)

 

CO

 

 

3 of 6

Item 1

 

  1(a)

Name of Issuer: Esperion Therapeutics, Inc.

 

  1(b)

Address of Issuer’s Principal Executive Offices:

3891 Ranchero Drive, Suite 150, Ann Arbor, MI 48108

Item 2

 

  2(a)

Name of Person Filing: BB Biotech AG (“BB Biotech”) on behalf of its wholly-owned subsidiary, Biotech Target N.V. (“Biotech Target”)

 

  2(b)

Address of Principal Business Office or, if none, Residence:

BB Biotech AG: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland

Biotech Target N.V.: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curaçao

 

  2(c)

Citizenship: BB Biotech AG: Switzerland

Biotech Target N.V.: Curacao

 

  2(d)

Title of Class of Securities Common Stock, par value $0.001 per share

 

  2(e)

CUSIP Number 29664W105

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

  (a)

Amount beneficially owned: 3,727,964

 

  (b)

Percent of class: 13.6%

 

  (c)

Number of shares as to which the person has:

 

  (i)

Sole power to vote or to direct the vote 0

 

  (ii)

Shared power to vote or to direct the vote 3,727,964

 

  (iii)

Sole power to dispose or to direct the disposition of 0

 

  (iv)

Shared power to dispose or to direct the disposition of 3,727,964

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

This statement is filed jointly by BB Biotech and Biotech Target, Biotech Target is a wholly-owned subsidiary of BB Biotech.

 

4 of 6

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BB Biotech AG

 

Date: February 13, 2020     By:  

/s/ Martin Gubler

      Signatory Authority
    Name:  

Martin Gubler

    Title:  

Signatory Authority

Date: February 13, 2020     By:  

/s/ Ivo Betschart

      Signatory Authority
    Name:  

Ivo Betschart

    Title:  

Signatory Authority

Biotech Target N.V.      
Date: February 13, 2020     By:  

/s/ Jan Bootsma

      Signatory Authority
    Name:  

Jan Bootsma

    Title:  

Signatory Authority

Date: February 13, 2020     By:  

/s/ Hugo van Neutegem

      Signatory Authority
    Name:  

Hugo van Neutegem

    Title:  

Signatory Authority

 

5 of 6

Exhibit Index

Exhibit A: Agreement by and between BB Biotech AG and Biotech Target N.V. with respect to the filing of this disclosure statement.*

 

 

*

Previously filed as an exhibit to BB Biotech AG and Biotech Target N.V.’s Schedule 13G filed with the Securities and Exchange Commission on September 27, 2016.

 

6 of 6